Dupilumab is safe and efficacious in treating moderate-to-severe AD in pediatric patients.

Guselkumab is efficacious in patients with moderate-to-severe psoriasis and a history of cancer.

Lutikizumab 300 mg was shown to be more effective than placebo in HS patients.

Apremilast is effective for the treatment of moderate-to-severe plaque psoriasis short-term in pediatric patients.

Plaque psoriasis patients with lower blood monocyte counts at baseline achieved early response when treated with secukinumab.

Biomarkers in the skin microbiota, antimicrobial peptides, and natural moisturizing factors m ay predict AD in infants.

Liquid synthetic detergents are better suited for maintaining healthy skin barrier function in AD patients.

The most effective AD treatments may also have the greatest risk of adverse events.